fluorouracil has been researched along with Carcinoma, Medullary in 13 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "Finally, unlike differentiated thyroid cancer, there is no known effective systemic therapy for MTC." | 2.43 | Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. ( Moley, JF; Quayle, FJ, 2005) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | 1.37 | [Primary systemic therapy in breast cancer patients (2007-2010)]. ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kucerova, L | 1 |
| Feketeova, L | 1 |
| Kozovska, Z | 1 |
| Poturnajova, M | 1 |
| Matuskova, M | 1 |
| Nencka, R | 1 |
| Babal, P | 1 |
| Zapf, I | 1 |
| Tizedes, G | 1 |
| Pavlovics, G | 1 |
| Kovács, G | 1 |
| Kálmán, E | 1 |
| Szalai, G | 1 |
| Kövér, E | 1 |
| Farkas, R | 1 |
| Horváth, OP | 1 |
| Mori, K | 1 |
| Chiba, N | 1 |
| Yamamoto, Y | 1 |
| Yonekawa, H | 1 |
| Quayle, FJ | 1 |
| Moley, JF | 1 |
| Labidi, SI | 1 |
| Gravis, G | 1 |
| Tarpin, C | 1 |
| Brun, V | 1 |
| Viens, P | 1 |
| Paiva, CE | 1 |
| Michelin, OC | 1 |
| Schlumberger, M | 2 |
| Abdelmoumene, N | 1 |
| Delisle, MJ | 1 |
| Couette, JE | 1 |
| Orlandi, F | 1 |
| Caraci, P | 1 |
| Berruti, A | 1 |
| Puligheddu, B | 1 |
| Pivano, G | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Behr, TM | 1 |
| Wulst, E | 1 |
| Radetzky, S | 1 |
| Blumenthal, RD | 1 |
| Dunn, RM | 1 |
| Gratz, S | 1 |
| Rave-Fränk, M | 1 |
| Schmidberger, H | 1 |
| Raue, F | 1 |
| Becker, W | 1 |
| Faris, M | 1 |
| Abraham, J | 1 |
| Barrett-Lee, P | 1 |
| Feng, J | 1 |
| Zheng, X | 1 |
| Dai, A | 1 |
| Nocera, M | 1 |
| Baudin, E | 1 |
| Pellegriti, G | 1 |
| Cailleux, AF | 1 |
| Mechelany-Corone, C | 1 |
1 review available for fluorouracil and Carcinoma, Medullary
| Article | Year |
|---|---|
Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitonin; Carcinoma, Medullary; Combined Modality | 2005 |
3 trials available for fluorouracil and Carcinoma, Medullary
| Article | Year |
|---|---|
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Combined Modality | 1995 |
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Dacarbazine; Fema | 1994 |
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Dacarbazine; Doxo | 2000 |
9 other studies available for fluorouracil and Carcinoma, Medullary
| Article | Year |
|---|---|
In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Carcinoma, Medullary; Carcinoma, Neur | 2014 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; | 2011 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
Medullary thyroid cancer treated by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Medullary; Cisplati | 2007 |
Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Medullary; Deoxycytidine; Fluoroura | 2008 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocol | 1997 |
A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: response to CMF chemotherapy.
Topics: Adult; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplasti | 1998 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |